Suzhou Zelgen Biopharmaceuticals Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 43.73 million. Revenue was CNY 43.73 million. Net loss was CNY 119.44 million compared to CNY 79.71 million a year ago. Basic loss per share from continuing operations was CNY 0.5 compared to CNY 0.33 a year ago. Diluted loss per share from continuing operations was CNY 0.5 compared to CNY 0.33 a year ago.